Marker Therapeutics (MRKR) reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s ...

Approximately 2% of Americans will be diagnosed with non-Hodgkin lymphoma during their lifetimes, according to NCI statistics.Follicular lymphoma — the most common subtype, often diagnosed in ...

A New Marker for Aggressive ... MD, Associate Professor, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center ... PD-1 expression in diffuse large B-cell lymphoma ...

Technological advances in gene cloning and genome-wide analyses have greatly increased the number of new tumor markers that can be detected by immunohistologic techniques. While many of these have ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancersFORT MYERS, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- ...

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma Marker Therapeutics Tue, May 20, 2025, 8:00 ...

This cancer is a subtype of non-Hodgkin lymphoma (NHL) and accounts for 6–10% of all NHL cases. PTCL can affect anyone, although it is slightly more common in males ages 60 years and over.

Mixed cellularity Hodgkin's lymphoma (MCHL) is a type of Hodgkin's lymphoma, which is a cancer that starts in the lymphatic system. Symptoms include painless swelling of the lymph nodes in the ...

HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...

HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...